The acquisition enhances ICON’s laboratory offering in molecular diagnostic testing and brings to ICON expanded testing platforms, including next generation sequencing, and immunohistochemistry (IHC).

“We are delighted to be joining ICON,” said Dan Snyder, president, MolecularMD. “Together with ICON, we can offer clients broader clinical trial and scientific expertise, more comprehensive testing capabilities and global scale to help them accelerate development timelines and reduce costs. We remain committed to providing agile clinical trial assay development across technology platforms and extending all the way through regulatory approval and commercialization of companion diagnostics.”

Steve Cutler, chief executive officer, ICON, said, “We are committed to expanding the testing we offer into specialized areas so that we can help customers to take time and cost from the development and commercialization of precision medicines. MolecularMD enhances our laboratory offering in molecular diagnostic testing, a key area in oncology research, and brings to ICON expanded testing platforms and diagnostic services. They have a strong reputation for innovation and quality and are a great addition to the ICON team.”